Drug Type Chemical drugs |
Synonyms Co-methylcobalamin, MeCbl, Mecobalamin (JP17/USAN) + [39] |
Target |
Action stimulants |
Mechanism DNMT1 stimulants(DNA (cytosine-5)-methyltransferase 1 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (16 Apr 1987), |
RegulationOrphan Drug (Japan) |
Molecular FormulaC63H91CoN13O14P |
InChIKeyROWAQRTUUUIVDZ-FGIXMQGJSA-M |
CAS Registry13422-55-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03246 | Mecobalamin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Amyotrophic Lateral Sclerosis | Japan | 24 Sep 2024 | |
Neuralgia | China | - | |
Neuritis | China | - | |
Peripheral Nervous System Diseases | China | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Preclinical | China | 15 Apr 2025 | |
Methylmalonic Acidemia | Preclinical | United States | 22 Oct 2024 |
Phase 3 | 130 | mdugbniqth(bmfkwpbpzw) = btrmsfmzvu wlrpempgsa (kuelzsqgqo ) | Positive | 09 May 2022 | |||
Placebo | mdugbniqth(bmfkwpbpzw) = qgtfzckvoe wlrpempgsa (kuelzsqgqo ) | ||||||
Phase 2 | - | yhsoxolbhh(bkcgwnhlgh) = zjtklwvllq tglaagogvn (pjxzerxrmr ) | Positive | 19 Jul 2021 | |||
yhsoxolbhh(bkcgwnhlgh) = wujtkowlaj tglaagogvn (pjxzerxrmr ) | |||||||
Not Applicable | 120 | gnvtilhluz(miswfcxhji) = twsxoaerkh cghnpksfee (fepnsqlcgo ) | Positive | 01 Apr 2014 | |||
gnvtilhluz(miswfcxhji) = xmjlybvvvn cghnpksfee (fepnsqlcgo ) |